Business Description
EQL Pharma AB
ISIN : SE0005497732
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.68 | |||||
Debt-to-EBITDA | 3.5 | |||||
Interest Coverage | 5.69 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 6.6 | |||||
Beneish M-Score | -1.85 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.8 | |||||
3-Year EBITDA Growth Rate | 55.3 | |||||
3-Year EPS without NRI Growth Rate | 26.1 | |||||
3-Year Book Growth Rate | 24.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 13.06 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 93.72 | |||||
9-Day RSI | 88.36 | |||||
14-Day RSI | 83.02 | |||||
6-1 Month Momentum % | 48.61 | |||||
12-1 Month Momentum % | 71.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.22 | |||||
Quick Ratio | 0.57 | |||||
Cash Ratio | 0.13 | |||||
Days Inventory | 213.67 | |||||
Days Sales Outstanding | 71.22 | |||||
Days Payable | 89.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.17 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.55 | |||||
Operating Margin % | 12.35 | |||||
Net Margin % | 8.6 | |||||
FCF Margin % | -29.7 | |||||
ROE % | 13.62 | |||||
ROA % | 7.26 | |||||
ROIC % | 10.32 | |||||
ROC (Joel Greenblatt) % | 35.01 | |||||
ROCE % | 18.13 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 57 | |||||
PE Ratio without NRI | 57 | |||||
Shiller PE Ratio | 141.35 | |||||
PEG Ratio | 0.77 | |||||
PS Ratio | 6.4 | |||||
PB Ratio | 9.32 | |||||
Price-to-Tangible-Book | 532 | |||||
EV-to-EBIT | 51.15 | |||||
EV-to-Forward-EBIT | 17.39 | |||||
EV-to-EBITDA | 51.15 | |||||
EV-to-Forward-EBITDA | 15.19 | |||||
EV-to-Revenue | 6.65 | |||||
EV-to-Forward-Revenue | 3.43 | |||||
EV-to-FCF | -22.6 | |||||
Price-to-Projected-FCF | 17.16 | |||||
Price-to-Median-PS-Value | 1.19 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.28 | |||||
Price-to-Graham-Number | 31.29 | |||||
Price-to-Net-Current-Asset-Value | 532 | |||||
Earnings Yield (Greenblatt) % | 1.96 | |||||
FCF Yield % | -4.69 | |||||
Forward Rate of Return (Yacktman) % | 19.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
EQL Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 23.037 | ||
EPS (TTM) (€) | 0.087 | ||
Beta | 0.88 | ||
Volatility % | 78.72 | ||
14-Day RSI | 83.02 | ||
14-Day ATR (€) | 0.176555 | ||
20-Day SMA (€) | 4.351 | ||
12-1 Month Momentum % | 71.89 | ||
52-Week Range (€) | 2.01 - 5.36 | ||
Shares Outstanding (Mil) | 29.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
EQL Pharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
EQL Pharma AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
EQL Pharma AB Frequently Asked Questions
What is EQL Pharma AB(FRA:7JK)'s stock price today?
When is next earnings date of EQL Pharma AB(FRA:7JK)?
Does EQL Pharma AB(FRA:7JK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |